Using known molecules, OptiNose deepens and broadens tissue penetration, offering the potential to tackle previously intractable challenges, such as delivery across the nose-brain barrier, without deposition to the lung.

Who should contact OptiNose?

  • Pharmaceutical and biotechnology companies interested in evaluating the nasal polyps or migraine applications
  • Those seeking an innovative, non-oral or non-injected delivery platform for their proprietary CNS, systemic or topical nasal compounds.
  • Companies seeking to re-evaluate promising compounds that experienced clinical development challenges due to insufficient oral bioavailability, first-pass metabolism, or speed of onset.
  • Companies seeking to find new or improved uses for existing compounds.

The Company offers both single and multi-use intranasal delivery devices for powder and liquid formulations.